Lyell Immunopharma, Inc. financial data

Symbol
LYEL on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 793 % -48.9%
Debt-to-equity 27.21 % +76.9%
Return On Equity -96.68 % -1.8%
Return On Assets -76 % -1.5%
Operating Margin -836,359 % -1.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21,218,217 shares -92.4%
Common Stock, Shares, Outstanding 19,293,951 shares -92.5%
Entity Public Float 306,000,000 USD -53.2%
Common Stock, Value, Issued 2,000 USD -92.3%
Weighted Average Number of Shares Outstanding, Basic 18,268,000 shares +42.6%
Weighted Average Number of Shares Outstanding, Diluted 18,268,000 shares +42.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41,000 USD -34.9%
Research and Development Expense 28,172,000 USD -28.7%
General and Administrative Expense 49,041,000 USD -3.2%
Operating Income (Loss) -342,907,000 USD -57.9%
Nonoperating Income (Expense) 17,247,000 USD +31.4%
Net Income (Loss) Attributable to Parent -325,660,000 USD -59.6%
Earnings Per Share, Basic 0 USD/shares +38.8%
Earnings Per Share, Diluted 0 USD/shares +38.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 123,575,000 USD +23.2%
Marketable Securities, Current 196,049,000 USD -42.4%
Assets, Current 328,201,000 USD -27.1%
Property, Plant and Equipment, Net 36,722,000 USD -58.3%
Operating Lease, Right-of-Use Asset 19,912,000 USD -45.7%
Other Assets, Noncurrent 2,545,000 USD -49.7%
Assets 407,965,000 USD -34.1%
Accounts Payable, Current 2,568,000 USD -28.6%
Liabilities, Current 31,878,000 USD -4.9%
Operating Lease, Liability, Noncurrent 44,285,000 USD -13.9%
Other Liabilities, Noncurrent 2,681,000 USD -24.8%
Liabilities 78,844,000 USD -10.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 201,000 USD -73.6%
Retained Earnings (Accumulated Deficit) -1,478,831,000 USD -28.2%
Stockholders' Equity Attributable to Parent 329,121,000 USD -38%
Liabilities and Equity 407,965,000 USD -34.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54,738,000 USD -30.3%
Net Cash Provided by (Used in) Financing Activities 27,000 USD
Net Cash Provided by (Used in) Investing Activities 69,466,000 USD +2.2%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 19,294,000 shares -92.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14,729,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 125,160,000 USD +24.4%
Deferred Tax Assets, Valuation Allowance 359,440,000 USD +44.7%
Deferred Tax Assets, Gross 366,357,000 USD +39.1%
Operating Lease, Liability 53,073,000 USD -9.4%
Payments to Acquire Property, Plant, and Equipment 246,000 USD +7.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -326,219,000 USD -61.5%
Lessee, Operating Lease, Liability, to be Paid 65,059,000 USD -13.3%
Property, Plant and Equipment, Gross 118,879,000 USD -23%
Operating Lease, Liability, Current 8,788,000 USD +23.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13,341,000 USD +9.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 12,959,000 USD +9.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11,986,000 USD -27.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13,005,000 USD +3.5%
Deferred Tax Assets, Operating Loss Carryforwards 176,298,000 USD +32.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits 3,659,000 USD +8.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10,398,000 USD -19.6%
Additional Paid in Capital 1,807,749,000 USD +7.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3,441,000 USD -31.5%
Deferred Tax Assets, Net of Valuation Allowance 6,917,000 USD -53.7%
Share-based Payment Arrangement, Expense 24,343,000 USD -27.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%